CL2008002411A1 - Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras. - Google Patents

Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.

Info

Publication number
CL2008002411A1
CL2008002411A1 CL2008002411A CL2008002411A CL2008002411A1 CL 2008002411 A1 CL2008002411 A1 CL 2008002411A1 CL 2008002411 A CL2008002411 A CL 2008002411A CL 2008002411 A CL2008002411 A CL 2008002411A CL 2008002411 A1 CL2008002411 A1 CL 2008002411A1
Authority
CL
Chile
Prior art keywords
compounds
myosin
broncho
glaucoma
hypertension
Prior art date
Application number
CL2008002411A
Other languages
English (en)
Spanish (es)
Inventor
Bradley MORGAN
Xiangping Qian
Bing Yao
Hong Jiang
Pu-Ping Lu
Chihyuan Chuang
Qing Lu
Wenyue Wang
David Morgans
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40350992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of CL2008002411A1 publication Critical patent/CL2008002411A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CL2008002411A 2007-08-15 2008-08-14 Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras. CL2008002411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96502007P 2007-08-15 2007-08-15

Publications (1)

Publication Number Publication Date
CL2008002411A1 true CL2008002411A1 (es) 2009-07-17

Family

ID=40350992

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002411A CL2008002411A1 (es) 2007-08-15 2008-08-14 Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.

Country Status (14)

Country Link
US (3) US8088793B2 (enExample)
EP (1) EP2195328A4 (enExample)
JP (1) JP5670731B2 (enExample)
KR (1) KR20100044251A (enExample)
CN (1) CN101821279A (enExample)
AR (1) AR069364A1 (enExample)
AU (1) AU2008287435B2 (enExample)
CA (1) CA2696321A1 (enExample)
CL (1) CL2008002411A1 (enExample)
MX (1) MX2010001692A (enExample)
NZ (1) NZ583351A (enExample)
PE (1) PE20090958A1 (enExample)
TW (1) TWI426908B (enExample)
WO (1) WO2009023193A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12281097B2 (en) 2016-04-27 2025-04-22 Biosplice Therapeutics, Inc. Isoquinolin-3-yl carboxamides and preparation and use thereof

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071625B2 (en) * 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8063082B2 (en) * 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
CN101821279A (zh) 2007-08-15 2010-09-01 赛特凯恩蒂克公司 某些化学个体、组合物和方法
CA2817460A1 (en) * 2010-12-17 2012-06-21 F. Hoffmann-La Roche Ag Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
US9725427B2 (en) * 2012-03-16 2017-08-08 Biohaven Pharmaceutical Holding Company Limited Prodrugs of riluzole and their method of use
WO2013151938A1 (en) * 2012-04-02 2013-10-10 Cytokinetics, Inc. Methods for improving diaphragm function
EP2875022B1 (en) 2012-07-19 2016-10-12 Cayman Chemical Company, Incorporated Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
WO2014144500A2 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN110678466B (zh) 2017-03-30 2023-01-31 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
JP7386841B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用
JP7386842B2 (ja) 2018-07-24 2023-11-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ナフチリジン化合物およびその使用
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
TW202023558A (zh) 2018-10-03 2020-07-01 美商建南德克公司 8-胺基異喹啉化合物及其用途
HU231754B1 (hu) * 2022-02-21 2026-02-28 Printnet Kereskedelmi és Szolgáltató Kft. 75% Sejtosztódási diszfunkciókkal és szöveti degenerációval járó kórképek kezelésében alkalmazható miozin 2 moduláló hatóanyagok

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3227709A (en) * 1961-11-28 1966-01-04 Merck & Co Inc Derivatives of cephalosporin c and process
GB1339764A (en) * 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
DE2851953A1 (de) 1978-12-01 1980-06-19 Thomae Gmbh Dr K Neue spectinomycylamine, verfahren zu ihrer herstellung und diese enthaltenden arzneimittel
JP2838148B2 (ja) * 1991-08-15 1998-12-16 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
JPH07247274A (ja) * 1994-03-10 1995-09-26 Wakamoto Pharmaceut Co Ltd ピバル酸 テトラゾリルフェニルエステル誘導体、それらを有効成分として含有するエラスターゼ阻害剤及び肺障害治療剤
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
WO1998041510A1 (en) * 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Novel benzolactam derivatives and medicinal compositions comprising the same
HUP0004200A3 (en) * 1997-11-18 2001-04-28 Dupont Pharmaceuticals Res Lab Cyclic amine derivatives and their use as drugs
US6107291A (en) * 1997-12-19 2000-08-22 Amgen Inc. Azepine or larger medium ring derivatives and methods of use
GB9807833D0 (en) * 1998-04-09 1998-06-10 Boc Group Plc Separation of air
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6410566B1 (en) * 2000-05-16 2002-06-25 Teijin Limited Cyclic amine derivatives and their use as drugs
CA2321348A1 (en) 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
TW200302728A (en) * 2002-02-01 2003-08-16 Novartis Ag Substituted amines as IgE inhibitors
RU2357962C2 (ru) * 2002-09-06 2009-06-10 Элан Фармасьютикалз, Инк. Пролекарственные производные 1,3-диамино-2-гидроксипропана
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
US20060178403A1 (en) 2003-03-07 2006-08-10 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
WO2005019177A1 (en) * 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
JP4380508B2 (ja) * 2003-11-28 2009-12-09 田辺三菱製薬株式会社 医薬組成物
EP1711175A1 (en) * 2004-02-04 2006-10-18 Active Biotech AB Diurea derivatives
CN104922117A (zh) * 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
WO2006137350A1 (ja) * 2005-06-22 2006-12-28 Kissei Pharmaceutical Co., Ltd. 新規なフロピリジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1942888A2 (en) * 2005-11-02 2008-07-16 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007109615A2 (en) 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US20070293530A1 (en) * 2006-06-14 2007-12-20 Methylgene Inc. Sulfamide and sulfamate derivatives as histone deacetylase inhibitors
US8063082B2 (en) 2006-08-02 2011-11-22 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8071625B2 (en) 2006-08-02 2011-12-06 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2008016676A2 (en) * 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
CN101821279A (zh) 2007-08-15 2010-09-01 赛特凯恩蒂克公司 某些化学个体、组合物和方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12281097B2 (en) 2016-04-27 2025-04-22 Biosplice Therapeutics, Inc. Isoquinolin-3-yl carboxamides and preparation and use thereof

Also Published As

Publication number Publication date
KR20100044251A (ko) 2010-04-29
NZ583351A (en) 2012-05-25
MX2010001692A (es) 2010-04-22
CN101821279A (zh) 2010-09-01
PE20090958A1 (es) 2009-08-07
CA2696321A1 (en) 2009-02-19
TW200922583A (en) 2009-06-01
TWI426908B (zh) 2014-02-21
US20120135964A1 (en) 2012-05-31
EP2195328A1 (en) 2010-06-16
WO2009023193A1 (en) 2009-02-19
US8759374B2 (en) 2014-06-24
US8088793B2 (en) 2012-01-03
US8895582B2 (en) 2014-11-25
AR069364A1 (es) 2010-01-20
JP2010536752A (ja) 2010-12-02
AU2008287435A1 (en) 2009-02-19
AU2008287435B2 (en) 2013-05-16
US20130053348A1 (en) 2013-02-28
EP2195328A4 (en) 2011-06-15
US20090275537A1 (en) 2009-11-05
JP5670731B2 (ja) 2015-02-18

Similar Documents

Publication Publication Date Title
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2008001114A1 (es) Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras.
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2007002866A1 (es) Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
CL2008001304A1 (es) Compuestos derivados de indol sustituido, inhibidores de la proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, enfermedad cardiovascular e inflamacion.
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CO6280490A2 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
CL2008001855A1 (es) Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa.
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
CL2008002006A1 (es) Compuestos derivados de morfolin pirimidina, composicion farmaceutica, y su uso como inhibidores de la m-tor-quinasa para el tratamiento de l a inflamacion, cancer, enfermedades inmunes, enfermedad obstructiva pulmonar, enfermedad cardiovascular.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
UY31484A1 (es) Piperidinas heteroaril-sustituidas